share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股SEC公告 ·  2024/06/24 07:05

Moomoo AI 已提取核心訊息

bluebird bio announced the appointment of Michael Cloonan to its Board of Directors as a Class I director, effective June 20, 2024. The appointment was approved by the company's Board of Directors.As per the company's Non-Employee Director Compensation Policy, Cloonan will receive an annual retainer of $45,000 for his Board service. Additionally, he has been granted an initial equity award consisting of stock options to purchase 74,775 shares of common stock and 37,350 restricted stock units. Both the stock options and restricted stock units will vest equally over a three-year period in annual installments.
bluebird bio announced the appointment of Michael Cloonan to its Board of Directors as a Class I director, effective June 20, 2024. The appointment was approved by the company's Board of Directors.As per the company's Non-Employee Director Compensation Policy, Cloonan will receive an annual retainer of $45,000 for his Board service. Additionally, he has been granted an initial equity award consisting of stock options to purchase 74,775 shares of common stock and 37,350 restricted stock units. Both the stock options and restricted stock units will vest equally over a three-year period in annual installments.
2024年6月20日,生物技術公司bluebird bio, Inc.[納斯達克上市代碼BLUE]宣佈任命邁克爾·克魯南(Michael Cloonan)爲其董事會I類董事,任期自同日起生效。作爲他的薪酬組成部分,克魯南將獲得45000美元的年度報酬,以及74,775股可購買公司普通股的股票期權和37,350股受限制的公司普通股。這些權益獎勵將在三年內分別以年度分期支付。此外,克魯南將參加公司的標準董事和高管賠款協議。該公司確認,克魯南與任何現任董事或執行官不具有家庭關係,也沒有與公司進行任何需要根據證券交易委員會監管披露的交易。該任命是公司不斷完善其治理和領導架構的一部分。
2024年6月20日,生物技術公司bluebird bio, Inc.[納斯達克上市代碼BLUE]宣佈任命邁克爾·克魯南(Michael Cloonan)爲其董事會I類董事,任期自同日起生效。作爲他的薪酬組成部分,克魯南將獲得45000美元的年度報酬,以及74,775股可購買公司普通股的股票期權和37,350股受限制的公司普通股。這些權益獎勵將在三年內分別以年度分期支付。此外,克魯南將參加公司的標準董事和高管賠款協議。該公司確認,克魯南與任何現任董事或執行官不具有家庭關係,也沒有與公司進行任何需要根據證券交易委員會監管披露的交易。該任命是公司不斷完善其治理和領導架構的一部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息